We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
A New Score Unveils a High Prevalence of Mild Cognitive Impairment in Patients with Nonalcoholic Fatty Liver Disease.
- Authors
Giménez-Garzó, Carla; Fiorillo, Alessandra; Ballester-Ferré, María-Pilar; Gallego, Juan-José; Casanova-Ferrer, Franc; Urios, Amparo; Benlloch, Salvador; Martí-Aguado, David; San-Miguel, Teresa; Tosca, Joan; Ríos, María-Pilar; Montón, Cristina; Durbán, Lucía; Escudero-García, Desamparados; Aparicio, Luis; Felipo, Vicente; Montoliu, Carmina
- Abstract
Patients with nonalcoholic fatty liver disease (NAFLD) may show mild cognitive impairment (MCI). The neurological functions affected remain unclear. The aims were to: (1) Characterize the neuropsychological alterations in NAFLD patients; (2) assess the prevalence of impairment of neurological functions evaluated; (3) develop a new score for sensitive and rapid MCI detection in NAFLD; (4) assess differences in MCI features between patients with nonalcoholic fatty liver (NAFL) and nonalcoholic steatohepatitis (NASH); and (5) compare neuropsychological alterations in NAFLD patients with cirrhotic patients with MCI. Fifty-nine NAFLD patients and 53 controls performed psychometric tests assessing different neurological functions: PHES (Psychometric Hepatic Encephalopathy Score) battery, d2, Stroop, Oral SDMT (Symbol Digit Modalities Test), Digit Span, number-letter test, and bimanual and visual-motor coordination tests. NAFLD patients show impairment in attention, mental concentration, psychomotor speed, cognitive flexibility, inhibitory mental control, and working memory. We developed a new, rapid, and sensitive score based on the most affected parameters in NAFLD patients, unveiling that 32% of NAFLD show MCI. Prevalence was similar in NAFL (36%) or NASH (27%) patients, but lower in NAFLD than in cirrhosis (65%). MCI prevalence is significant in NAFLD patients. Psychometric testing is warranted in these patients to unveil MCI and take appropriate measures to reverse and prevent its progression.
- Subjects
NON-alcoholic fatty liver disease; FATTY liver; MILD cognitive impairment; MEMORY span; NEUROPLASTICITY
- Publication
Journal of Clinical Medicine, 2021, Vol 10, Issue 13, p2806
- ISSN
2077-0383
- Publication type
Article
- DOI
10.3390/jcm10132806